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Pakistan is among top five high burden countries for tuberculosis and drug resistant TB.
Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is
8.3% (95%CI: 7.0–10.7) and resistance to fluoroquinolone is higher (11�1%, 95%CI: 7�8–
14�3) than isoniazid resistance.
Method
Five year retrospective data (2015–2019) of drug susceptibility testing (DST) for Mycobacte-
rium tuberculosis isolates, performed using recommended phenotypic (pDST) and/or geno-
typic (gDST) methods was analyzed stratified by rifampicin results for isoniazid resistance
profiles and associated levofloxacin and pyrazinamide resistance.
Findings
DST data was analyzed from 11045 TB patients. Isolates were tested using pDST (87%),
gDST (92%) and both methods (79.5%). For both rifampicin and isoniazid, a significant dif-
ference (P < .001) was noted between resistance detected by pDST and gDST. Among iso-
lates, tested by both methods (8787), 49% were resistant to rifampicin and 51.7% to
isoniazid with discordance in resistant results of 15.8% for each, with 13.2% (570) of rifampi-
cin resistance reported sensitive by pDST and 14.2% (660) of isoniazid resistance missed
by gDST. Estimated isoniazid resistance among rifampicin sensitive new PTB, extrapul-
monary TB and previously treated PTB was 9.8% (95%CI: 8.7–11.1), 6.8% (95%CI: 5.4–
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8.5) and 14.6% (95%CI: 11.8–17.9) respectively. Significant differences were reported
between the genotypic profile of isoniazid resistance associated with rifampicin-resistant
and sensitive isolates including detectable mutations (87% vs 71.6%), frequency of inhA
(7.6% and 30.2%) and katG mutations (76.1% vs 41.2%) respectively. Among rifampicin
resistant and sensitive isolates, a significantly higher level of resistance to levofloxacin and
pyrazinamide was seen associated with isoniazid resistance.
Conclusion
There are risks and many challenges in implementing WHO recommended treatment for
isoniazid resistant tuberculosis. The laboratory based surveillance can complement random
surveys in country specific planning for TB diagnostics and appropriate treatment regimens.
Introduction
Isoniazid (INH) is one of the most important first-line medicines for the treatment of active
tuberculosis (TB) with high bactericidal activity and a good safety profile [1–3]. Together with
rifampicin (RMP), the two drugs represent the cornerstone of World health organization
(WHO) recommended first-line treatment regimen used worldwide [4]. INH is also used in
high dose in short course second line treatment regimens for drug resistant TB (DRTB) [5].
INH is critical not only for the treatment of active TB, but it is also highly effective in prevent-
ing disease and is the most commonly used medicine for latent TB infection [6]. INH resis-
tance can thus undermine the effectiveness of treatment for both TB disease and infection.
Culture-based phenotypic testing is the current reference method for testing anti-TB medi-
cines. It relies on testing at critical concentrations of drugs, that is, the lowest concentration of
an anti-TB medicine that inhibits the in vitro growth of 99% of phenotypically wild-type
strains ofMycobacterium tuberculosis (Mtb) [7]. In 2008, WHO endorsed the first genotypic
drug susceptibility testing (DST) method for the rapid detection of multidrug-resistant (MDR)
TB. INH resistance has been associated with multiple genes, most frequently katG and inhA
[8–11]. The reported frequency of mutations varies in different geographical regions [11]. A
number of studies have reported that the mutation at codon 315 in katG gene is often associ-
ated with a high level of INH resistance whereas mutations in inhA gene are associated with
low-level resistance [8, 9].
Globally there are an estimated 10 million incident TB cases and among these, 7.0 million
were notified in 2018. A high treatment success rates of at least 85% for new TB cases is regu-
larly reported by all countries [7]. The estimated global prevalence of INH resistance among
RMP sensitive new and previously treated TB (RsHr-TB) is 7.4% (95%CI: 6.5%–8.4%) and
11.4% (95%CI:9.4%–13.4%) respectively [12]. People infected with a TB strain that is resistant
to INH, are reported to have a higher rate of unfavorable treatment outcomes with standard
first line treatment [13].
In 2019, WHO issued guidelines recommending a modified 6-month treatment regimen
containing RMP, ethambutol (EMB), pyrazinamide (PZA) and levofloxacin (LFX) for people
with RsHr-TB. Exclusion of resistance to RMP is strongly recommended and empirical treat-
ment is not advised. Fluoroquinolone (FQ) and PZA testing prior to treatment, is also advised
where possible in order to prevent the acquisition of additional drug resistance. In addition,
information on the specific INH mutations (katG or inhA) and overall host acetylator status at
country or regional level are considered useful for regimen design [5].
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Pakistan is country in South Asia with 212 M population and is among top five high burden
countries (HBC) for TB and drug resistant TB (DRTB) [7]. TB disease burden is estimated at
562K incident TB cases at 265 /100K population. DOTs is the official strategy for TB control in
the country and six month treatment regimen containing RMP throughout was adopted start-
ing from 2012. Treatment success rate is maintained above 90% for new TB patients. In 2018,
64% of the estimated TB cases were notified including 80% pulmonary TB (PTB) [7]. First
population based drug resistance survey (DRS) for smear positive PTB patients was conducted
in 2012–13 and prevalence of RMP resistance was estimated at 4.2% and MDR at 3.7% in new
cases. Any resistance to INH not associated with RMP resistance (RsHr-TB) was reported in
8.3% (95%CI: 7.0–10.7) of new and 7.1% (95%CI: 4.0–11.4) in previously treated PTB patients
[14]. Subsequently, DRS isolates were also tested for FQ and PZA resistance among RMP resis-
tant and sensitive population as part of a multicounty surveillance project and FQ resistance
was reported respectively in 21�8% (95%CI;13�1–30�5)and 11�1%(95%CI:7�8–14�3) and PZA
resistance in 39.5% (30.1–48.9) and 0.5%(0.1–0.8) [14, 15]. However there is limited published
data on molecular markers for INH resistance [12]. We analyzed routine laboratory data to
study diagnostic and clinical implications of the prevalent phenotypic and genotypic profile of
INH resistance and LFX and PZA resistance associated with INH resistance in RMP resistant
(RrHr) and sensitive (RsHr) isolates from pulmonary and extrapulmonary TB (EPTB)
patients.
Study setting, design and methodology
Study setting
In Pakistan, Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) testing services are decentralized,
patient reported to have RMP resistance are referred to specialized DRTB treatment sites and
specimens are than referred for DST. Specimen transport is well established between DRTB
treatment sites and culture and DST laboratories. National TB Reference laboratory (NTRL) is
located in Islamabad, the federal capital of the country and receive clinical specimens or cul-
ture isolates, referred routinely from treatment sites across Punjab province and three territo-
ries including Islamabad, Azad Jammu Kashmir and Gilgit Baltistan together covering more
than 50% of the country population. NTRL offer diagnostic and DST services for patients
already diagnosed as RMP resistant by Xpert MTB/RIF or who are at risk of drug resistance or
presumed to have TB specially PTB in children and EPTB.
Study design
This is a retrospective five-year (January 2015-December 2019) laboratory based surveillance
study. All confirmed Mtb isolates from patients having PTB or EPTB, tested either using phe-
notypic DST (pDST) and/or genotypic method (gDST) with DST results reported for both
RMP and INH were included.
Laboratory methods
Throughout the study period, gDST for RMP, INH and FQ was performed by Line Probe
assay(LPA), using GenoType MTBDRplus and MTBDRsl version 2.0 (Hain Lifescience, Neh-
ren, Germany). MGIT 960 automated system (BD, Sparks, MD, USA) was used to perform
pDST at recommended critical concentrations for RMP (1.0ug/ml), INH (0.1ug/ml), PZA
(100ug/ml) and ofloxacin (2ug/ml) during 2015–17 and LFX (1.0ug/ml) during 2018–19 [16].
All clinical samples were processed for culture and pDST was performed for all confirmed
Mtb isolates. LPA was introduced in late 2015 and gDST was increasingly performed directly
PLOS ONE Laboratory based surveillance of isoniazid resistance profile in tuberculosis patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0239328 September 23, 2020 3 / 20
on clinical samples from known RMP resistant patients. Culture isolates were used for gDST
for patients having RMP resistance with invalid results on direct testing, known RMP sensitive
or with unknown RMP status. Sequencing was not performed as facilities were not established.
All recommended quality control measures for DST were followed during study period
including, testing of known sensitive and resistant control strains with each batch of DST [17]
and regular participation in annual external quality assessments conducted by WHO collabo-
rating center (Supra National TB reference laboratory, ITM, Antwerp, Belgium) with success-
ful certification for first and second line DST.
Data management
Case based data was extracted from computerized laboratory information system of NTRL in
CSV format. Data was then checked for duplications, for each patient only first pDST and /or
gDST results reported either from same or paired samples were included. Duplicate or sequen-
tial DST results from same patient were excluded. After cleaning, all personal identifiers were
removed before analysis.
Data analysis
Data were analyzed using STATA1 v13.1 (StataCorp, 4905 Lakeway Drive, College Station,
Texas 77845, USA). Mean, median and quartiles were analyzed for quantitative variables and
95% confidence intervals for comparisons between groups. Two sample proportion test was
used to analyze differences in proportions between groups. A p-value of<0.05 was considered
statistically significant.
Study population was analyzed for demographic characteristics of patients, previous history
of TB treatment, province of residence, referring health facilities and AFB smear results. All
phenotypic and genotypic results were first analyzed independently for proportion of RMP
and INH resistance. Further analysis was done on large subset of Mtb isolates tested by both
DST methods. LPA results were interpreted based on recommended guidelines [18]. Results
were compared for agreement and discordance between two DST methods for RMP and INH.
For final interpretation, resistance conferring mutations to RMP and INH were considered to
be true resistance, even if phenotypic testing showed susceptibility. Based on the final interpre-
tations, prevalence of INH and RMP resistance, genetic profile of INH resistance and associ-
ated resistance to LFX and PZA was analyzed stratified by RMP result, disease site and
previous history of TB treatment. Genetic profiles of INH resistant isolates was studied for the
frequency of mutations known to confer resistance among samples displaying either pheno-
typic and/or genotypic resistance to INH. The INH resistant isolates were sorted into four
groups: Group1: phenotypic resistant but genotypic wild type (WT), Group 2: isolates with
inhAmutation/s only, Group 3: isolates with katGmutation only and Group 4: isolates with
combined katG and inhAmutations. Annual trends were analyzed for RsHr-TB, genetic pro-
file of INH resistance and associated FQ and PZA resistance.
Patient having no or unknown previous history of ATT were categorized as new and those
with history of previous treatment or on treatment for more than a month as previously
treated. For estimation of INH resistance among previously treated, data was analyzed only
from those patient with history of WHO recommended TB treatment for new TB patients.
Annual trend for INH resistance was analyzed for years with DST results available by both
methods for more than 100 patients. For FQ resistance, all strains reported resistant to OFX
(2015–17), LFX (2018–19) or showing FQ conferring mutations on LPA were considered LFX
resistant. Results were compared with the prevalence estimates of resistance reported in DRS
[14] and primary drug resistance in EPTB [19].
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Ethics statement
The study protocol was approved by IRB of Common unit for HIV/AIDS, TB and Malaria pro-
gram, Islamabad, Pakistan. The antimicrobial resistance was analyzed in Mtb strains isolated
routinely in the laboratory for diagnostic purposes. To maintain confidentiality of the patients,
de-identified data was used for analysis.
Results
Study population
During the study period (January 2015 to December 2019), altogether 11,680 DSTs were
reported, 635 were duplicate and/or sequential DST, which were excluded, and final analysis
was performed on 11,045 DST results from same number of patients (Fig 1). Patients included
were referred from 86 health facilities in 29 districts. Altogether 65.8% patients were referred
by tertiary care, 30.2% by secondary and 3.9% by primary health care facilities and 83.8% of
patient referral was from health facilities managing DRTB (S1 Table).
Median age of TB patients was 30 years (32 years for PTB and 23 years for EPTB), 7.5%
were children (<15yrs), 48.8% females and 86% were resident of Punjab province. Of all
patients, 87.3% presented with PTB, 56% of PTB and 8.3% of EPTB patients had a history of
previous TB treatment. Among previously treated PTB, 44.8% had history of TB treatment reg-
imen for new patients, 11.8% for retreatment and 22.4% for DRTB (S1 Table). Details of pul-
monary and extrapulmonary specimens processed for testing is given in S2 Table.
Rifampicin and isoniazid resistance
Rifampicin and isoniazid resistance by DST methods. Of all 11045 TB patients, pDST
results were available for 9620 including 14.1% (1352) EPTB, gDST for 10212 including 12.6%
(1282) EPTB and both pDST and gDST results for 8787 patients including 14.1% (1236)
EPTB. RMP and INH resistance detected by pDST and gDST is shown in Table 1 and annual
trend in S3 Table. Among PTB isolates, a significant difference (P< .001) was seen between
resistance detected by pDST and gDST for RMP (49.8 vs 56.4%) as well as INH (58.4 vs 49.2%)
respectively but difference was not significant among EPTB isolates (Table 1).
Correlation between genotypic and phenotypic DST results. Of all isolates tested by
both DST methods (n = 8787), an agreement in results was reported for both RMP and INH in
81% (7117), RMP in 92.3% (8109) and INH in 91.9% (8071) of isolates (Table 2; S3 and S4
Tables). A significant difference was seen between RMP resistance (P< .001) detected by
pDST (42.5%, 95%CI; 41.5–43.5) and gDST (47.7%, 95%CI; 46.7–48.8) and INH resistance (P
< .001) detected by pDST (51.1%, 95%CI; 50.0–52.1) and gDST (44.2%:95%CI 43.1–45.2).
Compared to pDST proportion of INH resistance by gDST was significantly lower among
RMP resistant (97.3 vs 83.1%) and RMP sensitive (16.9 vs 8.7%) isolates. Taking both DST
results into account, altogether RMP resistance was detected in 4303 (49%, 95%CI; 47.9–50.0)
isolates with 678 (15.8%) discordant results including 570(13.2%) reported sensitive by pDST
and 108(2.5%) by gDST. INH resistance was detected in 4542(51.7%, 95%CI; 50.6–52.7) iso-
lates with 716(15.8%) discordant result including 660(14.2%) reported sensitive by gDST and
56 (1.2%) by pDST. (Table 2; S4 Table).
Isoniazid resistance in rifampicin sensitive TB. Among RMP sensitive new PTB
(n = 2489) and EPTB (n = 1058) patients, INH resistance (RsHr-TB) was reported in 9.8%
(95%CI 8.7–11.1) and 6.8% (95%CI 5.4–8.5) respectively and 14.6% (95%11.8–17.9) among
patients treated previously for new TB (n = 547) (Table 3). A stable annual trend of RsHr-
TB was seen in new PTB and EPTB patients (Fig 2). A significant difference was reported in
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proportion of RsHr-TB between new PTB and EPTB (P = 0.004) and new and previously
treated PTB patients (P<0.01). Among new PTB, significant differences were not seen
between children and adults, male and females and resident of Punjab and other regions
(Table 3).
Fig 1. Flow diagram showing drug susceptibility testing of Mycobacterium tuberculosis isolates by disease site, history of TB treatment
and DST method, National TB reference laboratory, Pakistan 2015–2019. RMP-rifampicin, INH-isoniazid, R-resistant, S-sensitive,
pDST-phenotypic drug susceptibility testing; gDST-Genotypic drug susceptibility testing, Rr-rifampicin resistant, Rs-rifampicin sensitive,
Hr-isoniazid resistant, Hs-Isoniazid sensitive.
https://doi.org/10.1371/journal.pone.0239328.g001
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Molecular characterization of isoniazid resistant isolates
Among all RrHr-TB isolates, INH conferring mutations were detected in 87.1% (95%CI: 86.0–
88.1) compared to 71.6% (95%CI: 67.2-75-6) in RsHr-TB (P< .001). A significant difference
(P< .001) was also seen in frequency distribution for both katG (76.1% vs 41.2%) and inhA
(7.6% and 30,2%) mutations between RrHr-TB and RsHr-TB respectively (Table 4).
Table 1. Isoniazid and rifampicin resistance detected by phenotypic and genotypic DST methods in Mtb isolates from pulmonary and extrapulmonary TB patients,
National TB reference laboratory, Pakistan 2015–19.
All TB (n = 11045) Pulmonary TB (n = 9647) Extrapulmonary TB (n = 1398)
Isolates tested pDST gDST p+gDST pDST gDST p+gDST pDST gDST p+gDST
9620 10212 8787 8268 8930 7551 1352 1282 1236
Any rifampicin resistance
RMP resistant-n 4225 5146 4303 4117 5027 4185 108 119 118
RMP-resistant-% 43.9% 50.4% 49.0% 49.8% 56.3% 55.4% 8.0% 9.3% 9.5%
(95%CI) (42.9–44.9) (49.4–51.4) (47.9–50.0) (48.7–50.9) (55.2–57.3) (54.3–56.5) (6.6–9.6) (7.7–11.0) (8.0–11.3)
Any isoniazid resistance
INH resistant-n 5025 4557 4542 4828 4393 4360 197 164 182
INH resistant-% 52.2% 44.6% 51.7% 58.4% 49.2% 57.7% 14.6% 12.8% 14.7%
(95%CI) 51.2–53.2 43.7–45.6 50.6–52.7 57.3–59.5 48.2–50.2 56.6–58.9 12.7–16.6 11.0–14.7 12.8–16.8
Isoniazid resistance associated with rifampicin resistance (MDR)
RrHr/Rr-TB-n 4117/4225 4112/5146 4078/4303 4010/4117 4008/5027 3971/4185 107/108 104/119 107/118
RrHr/Rr-TB % 97.4% 79.9% 94.8% 97.4% 79.7% 94.9% 99.1% 87.4% 90.7%
(95%CI) (96.9–97.9) (78.8–81.0) (94.1–95.4) (96.0–97.9) (78.6–80.8) (94.2–95.5) (94.9–100) (80.0–92.8) (83.9–95.2)
Isoniazid resistance associated with rifampicin susceptible (RsHr)
RsHr/Rs-TB-n 908/5395 445/5066 464/4484 818/4151 385/3903 389/3366 90/1244 60/1193 75/1118
RrHr/Rs-TB-% 16.8% 8.8% 10.3% 19.7% 9.9% 11.6% 7.2% 5.2% 6.7%
(95%CI) (15.8–17.9) (8.0–9.6) (9.5–11.3) (18.5–20.9) (8.9–10.8) (10.5–12.7) (5.9–8.8) (1.7–6.8) (5.4–7.2)
N = number isolates tested, n = number resistant, pDST = Phenotypic drug susceptibility testing, gDST = Genotypic drug susceptibility testing
https://doi.org/10.1371/journal.pone.0239328.t001
Table 2. Correlation between phenotypic and genotypic drug susceptibility testing results for rifampicin and isoniazid in Mtb isolates from all type TB patients,
National TB reference Laboratory Pakistan 2015–19.
All Rifampicin
phenotypic(MGIT960) and genotypic(LPA) DST results
pRgR pRgS pSgR pSgS pRgNA pSgNA pNAgR pNAgS
Isoniazid phenotypic(MGIT960)and genotypic (LPA) DST
results
All 11045 3625 108 570 4484 492 341 951 474
pRgR 3826 3097 66 352 311
pRgS 660 431 38 59 132
pSgR 56 9 26 21
pSgS 4245 88 4 133 4020
pRgNA 539 485 54
pSgNA 294 7 287
pNAgR 675 628 47
pNAgS 750 323 427
Isoniazid
Resistant
RrHr% 97.6% 96.3% 76.7% 98.6% 66.0%

















p-phenotypic, g-genotypic, DST-drug susceptibility testing, S-sensitive, R-Resistant, NA-not available.
https://doi.org/10.1371/journal.pone.0239328.t002
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Rifampicin resistant TB. Among 3971 RrHr-PTB isolates, 13.1% (519) were wild type
(WT) on LPA. Genetic mutations associated with INH resistance were detected in inhA in
7.6% and katG in 76.1%, and combined katG and inhAmutations in 3.1%. Among 107 RrHr-
EPTB isolates, 8.4% (9) were genotypic WT, mutations were detected in inhA in 10.3%, katG
in 79.4%, and double mutation in 2 isolates (1.9%) only. A significant difference was not seen
between PTB and EPTB (Table 4), new and previously treated (S5 Table) and annual trends
(Fig 3; S6 Table).
Among all MDR isolates (PTB and EPTB), the most frequent mutation were reported in
codon S315T1 (97.2%, 3028/3112) in katG gene and C-15T in InhA promoter region (92.3%,
287/311) (Table 4).
Rifampicin sensitive TB. Among 389 RsHr-PTB isolates, 29.6% (115) were genotypic
WT, INH conferring mutations were detected in inhA in 29.6%, katG gene in 40.6% and dou-
ble mutation in only one isolate. Among 75 RsHr-EPTB isolates, 22.7% (17) were WT on LPA,
INH conferring mutations were detected in inhA in 33.3%, katG in 44%, with no double muta-
tion. Significant differences were not noted between isolates from PTB and EPTB (Table 4),
Table 3. Isoniazid resistance among rifampicin sensitive new and previously treated pulmonary and extrapulmonary TB patients, national TB reference laboratory,
Pakistan 2015–2019.
Pulmonary TB Extrapulmonary TB
New PT� p-value New PT� p-value
All Patients 245/2489;9.8% 80/547;14.6% <0.01 72/1058;6.8% 3/60;5.0% 0.588
(8.7–11.1) (11.8–17.9) (5.4–8.5) (1.0–13.9)
Gender
Male 119/1263;9.4% 45/290;15.5% 0.002 28/533;5.3% 1/31;3.2% 0.608
(7.9–11.2) (11.5–20.2) (3.5–7.5) (0.08–16.7)
Female 126/1226;10.3% 35/257;13.6% 0.122 44/525;8.4% 2/29;6.9% 0.776
(8.6–12.1) (9.7–18.4) (6.2–11.1) (0.8–22.8)
Age Group
Children(<15yrs) 36/302:11.9% 7/31:22.6% 0.09 11/184:6.0% 0/6:0.0% 0.536
(8.5–16.1) (10.0–41.1) (3.0–10.4) (0.0–45.9)
Adult 204/2147:9.5% 72/508:14.2% 0.002 61/869:7.0% 3/54:5.6% 0.694
(8.3–10.8) (11.3–17.5) (5.4–8.9) (1.1–15.4)
Age NA 5/40:12.5% 1/8:12.5% 0/5:0.0% 0/0
(4.2–26.8) (0.03–52.7) 0.00% 0.00%
Place of Residence
Punjab province 211/2041;10.3% 64/446;14.3% 0.015 61/871;7.0% 3/48;6.3% 0.853
(9.1–11.7) (11.2–18.0) (5.4–8.9) (1.3–17.2)
Outside Punjab 34/448;7.6% 16/101;15.8% 0.01 11/187;5.9% 0/12;0.0% 0.387
(5.3–10.4) (9.3–24.4) (3.0–10.3)
AFB smear Results
Positive 95/903;10.5% 65/385;16.9% 0.001 8/128;6.3% 0/17;0.0% 0.287
(8.7–12.7) (13.3–21.0) (2.7–11.9) (0.0–19.5)
Negative 41/516;7.9% 7/86;8.1% 0.949 19/303;6.3% 2/34;5.9% 0.927
(5.9–10.6) (3.3–16.1) (3.8–9.6) (0.7–19.7)
Not available 109/1070;10.2% 8/76;10.5% 0.934 45/627;7.2% 1/9;11.1%
(8.4–12.2) (4.7–19.7) (5.3–9.5) (0.2–48.2)
Number shown are number isoniazid resistant/ number rifampicin susceptible isolates tested, % isoniazid resistant (95%CI)
�PT; previously treated with treatment regimen recommended for new TB patients
https://doi.org/10.1371/journal.pone.0239328.t003
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Fig 2. Trend of isoniazid resistance in rifampicin sensitive new pulmonary TB, new extrapulmonary TB and previously treated pulmonary TB patients,
National TB reference laboratory, Pakistan, 2015–19. RsHr; Rifampicin sensitive isoniazid resistant.
https://doi.org/10.1371/journal.pone.0239328.g002
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new and previously treated (S5 Table) and annual trends. A more stable annual trend was seen
for katG compared to inhAmutations. (Fig 3; S6 Table).
Associated levofloxacin and pyrazinamide resistance
Among RMP resistant PTB isolates, resistance to LFX and PZA was reported respectively in
47.7% (95%CI: 46.2–49.2) and 44.8% (95%CI: 43.2–46.4) compared to 14.4% (13.3–15.7) and
3.7%, (95%CI: 3.0–4.5) in RMP sensitive. Similar pattern was seen in EPTB (Table 5; S7
Table).
Rifampicin resistant TB. Among RrHr-PTB isolates(n = 3969), resistance to LFX, PZA
and combined LFX and PZA was 49%, 47% and 27.9%, which was higher compared to
Table 4. Molecular characterization of isoniazid resistance in rifampicin resistant and sensitive Mtb isolates from pulmonary and extrapulmonary TB patients,
National TB reference laboratory Pakistan 2015–19.
All-TB RrHr-TB RsHr-TB RrHr-TB RsHr-TB
PTB EPTB PTB EPTB
INH resistant isolates N = 4542 N = 4078 N = 464 N = 3971 N = 107 N = 389 N = 75
gWTpNWT 660 14.5% 528 12.9% 132 28.4% 519 13.1% 9 8.4% 115 29.6% 17 22.7%
Any Mutation 3882 85.5% 3550 87.1% 332 71.6% 3452 86.9% 98 91.6% 274 70.4% 58 77.3%
katG_S315T 3213 70.7% 3028 74.3% 185 39.9% 2943 74.1% 85 79.4% 153 39.3% 32 42.7%
katG_315 90 2.0% 84 2.1% 6 1.3% 84 2.1% 0.0% 5 1.3% 1 1.3%
inhA_c-15t 411 9.0% 287 7.0% 124 26.7% 277 7.0% 10 9.3% 101 26.0% 23 30.7%
inhA_-15 17 0.4% 8 0.2% 9 1.9% 8 0.2% 0.0% 9 2.3% 0.0%
inhA_t-8c 10 0.2% 8 0.2% 2 0.4% 8 0.2% 0.0% 1 0.3% 1 1.3%
inhA_-8 5 0.1% 3 0.1% 2 0.4% 2 0.1% 1 0.9% 2 0.5% 0.0%
inhA_t-8a 6 0.1% 3 0.1% 3 0.6% 3 0.1% 0.0% 2 0.5% 1 1.3%
inhA_-15,-8 1 0.0% 1 0.0% 0 0.0% 1 0.0% 0.0% 0.0% 0.0%
inhA_c-15t & t-8c 1 0.0% 1 0.0% 0 0.0% 1 0.0% 0.0% 0.0% 0.0%
katG_S315T inhA_c-15t 84 1.8% 84 2.1% 0 0.0% 84 2.1% 0.0% 0.0% 0.0%
katG_S315T inhA_t-8c 27 0.6% 27 0.7% 0 0.0% 25 0.6% 2 1.9% 0.0% 0.0%
katG_S315T inhA_t-8a 4 0.1% 4 0.1% 0 0.0% 4 0.1% 0.0% 0.0% 0.0%
katG_315 inhA_c-15t 6 0.1% 5 0.1% 1 0.2% 5 0.1% 0.0% 1 0.3% 0.0%
katG_S315T inhA_-15 3 0.1% 3 0.1% 0 0.0% 3 0.1% 0.0% 0.0% 0.0%
katG_S315T inhA_-8 3 0.1% 3 0.1% 0 0.0% 3 0.1% 0.0% 0.0% 0.0%
katG_S315T inhA_a-16g 1 0.0% 1 0.0% 0 0.0% 1 0.0% 0.0% 0.0% 0.0%
Summary
gWTpNWT–n % 660 14.5% 528 12.9% 132 28.4% 519 13.1% 9 8.4% 115 29.6% 17 22.7%
(95%CI) (13.5–15.6) (11.9–14.0) (24.4–32.8) (12.0–14.2) ( 3.9–15.4) ( 25.1–34.4) (13.8–33.8)
p-value <0.01 0.153 0.225
katG mutation-n % 3303 72.7% 3112 76.3% 191 41.2% 3027 76.2% 85 79.4% 158 40.6% 33 44.0%
(95%CI) (71.4–74.0) (75.0–77.6) (36.6–45.8) (74.9–77.5) (70.5–86.6) (35.7–45.7) (35.5–55.9)
p-value <0.01 0.443 0.584
inhAmutation- n % 451 9.9% 311 7.6% 140 30.2% 300 7.6% 11 10.3% 115 29.6% 25 33.3%
95%CI (9.1–10.8) (6.8–8.5) (26.0–34.4) (6.8–8.4) (5.2–17.7) (25.1–34.3) (22.9–45.2)
p-Value <0.01 0.300 0.523
Double Mutation- n % 128 2.8% 127 3.1% 1 0.2% 125 3.1% 2 1.9% 1 0.3% 0 0.0%
95%CI (2.4–3.3) (2.6–3.7) (0.0–1.2) (2.6–3.7) (0.2–6.6) ( 0.007–1.4) (0.00–46.9)
p-value 0.187 0.478 0.129
RrHr-Rifampicin resistant Isoniazid resistant, RsHr-Rifampicin sensitive Isoniazid resistant
https://doi.org/10.1371/journal.pone.0239328.t004
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Fig 3. Trend of isoniazid resistance profiles associated with rifampicin resistant and rifampicin sensitive isolates, National TB reference laboratory, Pakistan
2015–19.
https://doi.org/10.1371/journal.pone.0239328.g003
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Table 5. Levofloxacin and pyrazinamide resistance associated with isoniazid resistance in rifampicin resistant
and sensitive Mycobacterium Tuberculosis isolates from pulmonary and extrapulmonary Tuberculosis patients,
National TB reference laboratory 2015–2019.
Isoniazid
resistance profile
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reported resistance in RrHs-TB (n = 214) of 23.8%, 6.4% and 3.0%. Similarly among RrHr-
EPTB (n = 107) reported resistance of 48.6%, 61.7% and 33.0% was higher compared to 9.1%,
0% and 0% in RrHs-TB (n = 11) (Table 5).Within RrHr-TB, significant difference in resistance
was not seen between PTB and EPTB (P = .08) (Table 5), new and previously treated TB (P =
.956) (S7 Table) and annual trends (S8 Table).
Rifampicin sensitive TB. Among RsHr-PTB(n = 389), resistance to LFX, PZA and com-
bined LFX and PZA, isolates was reported in 25.2%, 12.2% and 6.4% respectively compared to
13.0%, 3.7% and 1.0 in RsHs-PTB(n = 2976). Among RsHr-EPTB (N = 75)isolates, resistant
was reported respectively in 6.7%, 8.8% and 0% compared to 7.2%, 2.8% and 0.2% in RsHs-
EPTB (N = 1042).No significant changes were see in the annual trend of resistance to LFX and
PZA. (S8 Table).
Isoniazid conferring mutations and Levofloxacin and pyrazinamide resistance.
Among RrHr-PTB isolates, a relative higher resistance to LFX was seen in isolates with double
mutations and relative higher resistance to PZA and combined LFX and PZA resistance was
seen associated with katG and double mutations. (Table 5; S7 Table; S1 Fig).
Discussion
We analyzed a large DST data set from 11045 patients registered during 2015–2019 in NTRL,
Pakistan. During the study period, pDST was performed on 87%, gDST on 92% and 79.5% of
isolates were tested by both methods. We analyzed results of 8787 Mtb isolates including 1236
from EPTB patients, tested by both phenotypic and genotypic methods. Key findings of our
analysis include significant difference in resistance detected by WHO recommended pDST
(MGIT 960) and gDST (LPA) methods for both RMP and INH, a significantly lower sensitivity
of gDST to detect INH resistance in RMP sensitive TB, difference in genetic profiles of INH
resistance associated with RMP resistant and sensitive TB, a higher level of LFX and PZA resis-
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we noted a stable annual trend of INH resistance in RMP sensitive new TB patients, INH resis-
tance profiles, associated FQ and PZA resistance and INH resistance missed by gDST method.
We reported, an INH resistance of 9.8% (95%CI; 8.7–11.1) in new and 14.6% (95%CI:
11.8–17.9) in previously treated RMP sensitive PTB patients. Among new PTB, a higher point
estimates compared to the estimates of DRS (8.3%, 95%CI: 7.0–10.7) conducted in 2013 [14]
can be explained based on the possibility of a selected higher risk individuals among new RMP
sensitive patients referred for testing in routine settings. However a stable RsHr resistance
trend was seen during the study period with an insignificant increase only in 2019. Among
previously treated, compared to DRS, the proportion of RsHr-TB was significantly higher but
fluctuations were seen in annual trends. Fluctuation in resistance was most likely due to varia-
tion in proportion of relapse vs failures of previous treatment among patient tested. However,
a higher RsHr reported among previously treated was consistent with findings of other similar
studies from Pakistan [20–22]. Among children with PTB (n = 302), estimated RsHr-TB of
11.9%(8.5–16.1), was higher but not statistically different from adults(p = .189) and was consis-
tent with the global estimates of 12.1% (95%CI:9.8% to 14.8%) among all childhood TB cases
[23]. However prevalence estimates in children can also be argued as not being a true represen-
tative of childhood TB population as most likely specimens from sicker children having access
to specialized TB care and diagnostic facilities were tested. Among RMP sensitive new EPTB
patient (n = 1058), INH resistance of 6.8% (95%CI; 5.4–8.5) was significantly lower compared
to PTB (P< .001) in same study population but was consistent with primary drug resistance
(5.6%, 95CI; 2.7–10.0) reported in EPTB [19] and PTB in Pakistan [14, 20, 24]. Most of the
EPTB patients in contrast to PTB, were referred for diagnosis of TB and only a few had history
of previous TB treatment (<10%), with possibility of these estimates being a true reflection of
RsHr in EPTB at population level.
Among Mtb isolates tested by both methods (n = 8787), discordance in RMP results was
reported in 7.7% of all and 15.8% (678/4303) of RMP resistant isolates. Discordance in RMP
results was also reported previously in random population-based DRS (2013) in which all sam-
ples were tested in parallel using Xpert MTB/Rif and Lowenstein Jensen (LJ) media and
sequencing was performed to confirm and resolve discordance in RMP results [14]. However
in DRS, discordance of 11.7% was reported among all RMP resistant isolates, including 4% (4/
104) missed on pDST and 7.7% (8/104) by gDST. Contrary to DRS, in this study 13.2%
(n = 570) were missed by MGIT (pDST) and 2.5% (n = 108) by LPA (gDST). The most plausi-
ble explanation for a higher number of observed missed RMP resistance by pDST (13.2% vs
4%) in study sample was due to use of automated liquid DST (MGIT), which is known to miss
higher proportion of RMP resistant cases compared to LJ media [25, 26]. On the other hand
the lower proportion of RMP resistant cases missed by gDST (7.7% vs 2.5%) was most likely
an effect of the current diagnostic algorithm followed in programme settings in which patients
reported RMP sensitive are initiated on standard first line treatment and are not investigated
further unless they fail to respond or fail treatment.
Recently conducted systematic review and meta-analysis, reported significant higher failure
rate among INH resistant compared to susceptible TB patients when treated with standard
first-line drugs regimens [13]. Limitations of currently available pDST and gDST in detecting
RMP resistance are well recognized [25–27]. Selection of either one of the two DST method
for routine practice is likely to result in important diagnostic and clinical implications. In our
study population, without genotypic DST, 10.1% (411/4078) of the MDR would have been
reported as RsHr-TB and treatment in these instances with standard first line treatment regi-
men would likely have resulted in suboptimal treatment outcomes. In a recently published
study, a non-negligible extent of misclassifying MDR-TB as INH-resistant TB is demonstrated
and impact of treating patients with missed RMP resistance for RsHr-TB with WHO
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recommended FQ containing regimen is strongly argued [27]. In another study from South
Africa 15% of INH resistant isolates initially tested negative for RMP resistance by all three
WHO-endorsed commercial tests were reclassified as MDR on identification of resistance
conferring mutation (rpoB Ile491phe) using deep sequencing [28].
In our data set, contrary to RMP, a higher proportion of INH resistance (14.5%; n = 660)
was missed by gDST. Our finding are consistent with the results of a recent study from eastern
DRC, in which INH resistance was reported in only 55% of the RMP resistant cases detected
by Xpert MTB/RIF on subsequent testing by LPA, raising an argument on use of RMP resis-
tance as surrogate marker for MDR [29].
We studied 4542 INH resistant isolates for molecular markers and mutations causing INH
resistance were identified in 85.5% with frequency of katG, inhA and combined katG and inhA
mutations in 72.7%, 9.9% and 2.8% respectively. Our findings are consistent with the pub-
lished data [11, 12, 30] but with a lower proportion of combined katG and inhAmutations in
our population [12, 31]. INH resistance profiles when studied, stratified by RMP results, signif-
icant differences were reported between RrHr-TB (n = 4078) and RsHr-TB(n = 464) with
regard to proportion of INH conferring mutation detected (87.1% vs 71.6%) and frequency of
the mutations in inhA (7.6 vs 30.2%), katG (76.3 vs 41.2%) and combined inhA and katG
(3.1% vs 0.2%). The distribution of INH resistance mutations among RsHr-TB is less well
mapped globally, however our findings are consistent with the estimates from an international
collection of over 5,000 strains with reported frequency of S315T katG in 88.7% of MDR and
61.3% of RsHr-TB showing substantially higher representation of katG among MDR strains
[32].
In our study population of RsHr-TB, 41% had mutation in katG, 30% in inhA and only one
isolates had combined mutation. Published data on the influence of genotype on treatment
outcomes of RsHr-TB are conflicting, study from Vietnam, suggest that katGmutations and
not inhA are associated with unfavorable treatment outcomes [33]. Whereas in a study from
South Africa, no evidence was found suggesting that specific isoniazid resistance conferring
mutations are associated with poor treatment outcomes, and results showed that patients with
katGmutations had greater odds of successful outcome when treated with high-dose isoniazid
compared to those who received standard dose [34].Few studies have also evaluated the effec-
tiveness of high-dose isoniazid in patients with DRTB and limited data available suggest clini-
cal benefit without a higher toxicity [35, 36]. A recent study has demonstrated that high dose
INH in MDR patients with inhAmutations has similar magnitude of bactericidal activity as
with standard doses in drug-susceptible TB patients [37].
In Pakistan, one of the key challenge for treating MDR-TB and RsHr-TB is high FQ resis-
tance. We reported a higher FQ resistance in RMP resistant and sensitive isolates compared to
population level resistance [12, 15] but was consistent with previous laboratory based study
from Pakistan [38]. In RMP resistant and sensitive population, significantly higher resistance
to LFX and PZA was noted associated with INH resistance and was statistically higher for all
INH resistance profiles. However a relative higher resistance was seen associated with com-
bined katG and inhAmutations, consistent with findings of a recent study [31]. A high LFX
resistance and lower frequency of katGmutations in RsHr-TB in our study population imply
consideration for high dose INH rather than LFX as a treatment option.
The End TB Strategy released in 2015 calls for the early diagnosis of TB including universal
DST [39]. Xpert MTB/RIF assay was endorsed by WHO in 2010, however even in 2018,
among bacteriologically confirmed TB patients, only 51% globally and 45% in Pakistan were
tested for RMP resistance [7]. Diagnostic and operational challenges to implement universal
INH testing and treatment for INH resistant TB, are more complex, because of the larger pop-
ulation of RMP sensitive patients and complex laboratory capacity required for testing in the
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absence of a rapid and convenient diagnostic platform for detection of INH resistance and
challenges faced in decentralization of LPA in most of HBC settings. Additionally in Pakistan
country context, even with systematic testing, 30 percent of the INH resistance are likely to be
missed if tested by LPA only, second, there is lack of laboratory capacity to systematically
exclude RMP resistance which are missed by Xpert MTB/Rif, third, high LFX resistance makes
FQ testing mandatory for all and lastly, FQ resistance in a substantial number of RsHr-TB
patients will render them ineligible for recommended treatment.
Currently HBC are struggling to develop capacity for comprehensive second line DST
including new and repurpose drugs [5] and to establish sequencing capacity to diagnose RMP
and other drug resistance not detected by routine tests. Plans to implement universal testing
and treatment for INH resistant TB with existing capacity are likely to overwhelm laboratory
systems at the cost of compromising services for RMP resistant TB patients. A new GeneXpert
cartridge for testing INH and FQ resistance is expected to be available in near future [40, 41],
however countries will need to invest in procurement of next generation modules and to make
it available at same level of health care as RMP testing for detection of INH and FQ resistance
in RMP sensitive TB patients in parallel with plans to implement treatment for INH resistance.
In addition performance evaluation of new diagnostic tests in both RMP resistant and sensitive
population in different geographical settings also needs consideration.
The value of any such laboratory study would be greatly increased if treatment outcomes
could be linked to the resistance profile. Studies are also needed to fill knowledge gap in isonia-
zid acetylator status of the population in HBC and to evaluate effectiveness, optimal dosing
and potential toxicity of high-dose isoniazid to offer simple treatment options applicable in
program settings.
We studied retrospective data and possibility of errors in routinely collected patient infor-
mation cannot be excluded. Furthermore findings of this study cannot be generalized to the
population level. However laboratory based surveillance can complement random survey as
analysis provides information on drug resistance pattern in a large dataset of DRTB patients at
time of treatment initiation and can guide in country specific planning for TB diagnostics,
diagnostic algorithm and appropriate treatment regimens for drug resistance in TB patients.
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